Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma
Christie P.M. Verkleij, Chloe O’Neill, Marloes E.C. Broekmans, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 14, pp. 3006-3022
Closed Access | Times Cited: 16

Showing 16 citing articles:

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
Luciano J. Costa, Rahul Banerjee, Hira Mian, et al.
Leukemia (2025)
Open Access | Times Cited: 4
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
Carlyn Tan, Sireesha Asoori, Chiung‐Yu Huang, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
Paola Neri, Noémie Leblay, Holly Lee, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 8, pp. 590-609
Closed Access | Times Cited: 7
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies
Niels W.C.J. van de Donk, Ajai Chari, María‐Victoria Mateos
The Lancet Haematology (2024) Vol. 11, Iss. 9, pp. e693-e707
Closed Access | Times Cited: 5
Bispezifische Antikörper in der Therapie hämatologischer Neoplasien und solider Tumoren
Xiang Zhou, Johannes M. Waldschmidt, Hermann Einsele
Deleted Journal (2025)
Open Access
Функциональное излечение как новая концепция терапии множественной миеломы
С. В. Семочкин
Clinical oncohematology (2025) Vol. 18, Iss. 2, pp. 105-120
Open Access
Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies
Per Ljungman, Sophie Alain, Roy F. Chemaly, et al.
The Lancet Infectious Diseases (2025)
Closed Access
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS
Katia Mancuso, Marco Talarico, Enrica Manzato, et al.
Cancers (2025) Vol. 17, Iss. 9, pp. 1514-1514
Open Access
The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma
Laura Sun, Jason T. Romancik
Journal of Personalized Medicine (2025) Vol. 15, Iss. 2, pp. 51-51
Open Access
Mechanistic insights into resistance mechanisms to T cell engagers
Liping Cao, Gabrielle Leclercq-Cohen, Christian Klein, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma
Yue Guo, Jin Niu, Natalia A. Quijano Cardé, et al.
Targeted Oncology (2025)
Open Access
Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: where do we stand today?
Xiang Zhou, K. Martin Kortuem, Leo Rasche, et al.
La Presse Médicale (2024), pp. 104265-104265
Open Access | Times Cited: 2
Comprehensive review of bispecific antibody constructs in multiple myeloma: affinities, dosing strategies and future perspectives
Johannes M. Waldschmidt, Leo Rasche, K. Martin Kortüm, et al.
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access | Times Cited: 1
Advancements in Bispecific Antibodies for Multiple Myeloma: What's New and What Lies Ahead
Tarek H. Mouhieddine, Bruno Almeida Costa, Joshua Richter
Seminars in Hematology (2024)
Closed Access | Times Cited: 1
T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement
Marise R. Heerma van Voss, Remco J. Molenaar, Charlotte L.B.M. Korst, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 9, pp. 889-901
Open Access | Times Cited: 1
A comeback for checkpoint inhibition in multiple myeloma
Maximilian Merz
Nature Cancer (2024) Vol. 5, Iss. 10, pp. 1449-1451
Closed Access
BCMA bispecifics: breaking the chains of resistance
Johannes M. Waldschmidt, Leo Rasche
Blood (2024) Vol. 144, Iss. 25, pp. 2566-2568
Closed Access
Page 1

Scroll to top